Anthony Rosenberg

Tony Rosenberg has served as Chairman of Oculis SA since April 2018. He is currently the CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing, and mergers and acquisitions and is also an Executive Advisor to PJT Ltd, London. Mr. Rosenberg has been also a Managing Director of MPM Capital, a venture capital firm, from 2015 to 2020 and previously served as Corporate Head of M&A and Licensing at Novartis A.G. and before that the Global Head of Business Development and Licensing at Novartis Pharma. Mr. Rosenberg is on the Board of Directors at Radius Health, TriNetX, Cullinan Oncology Inc., argenx BV and SiO2 Materials Sciences. He holds a B.Sc. (Hons) from the University of Leicester and a M.Sc. Physiology from the University of London.